PS Ratio: 14.88

Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

Is the P/S ratio high or low?

The P/S ratio of 14.88 is 100% below its estimated 5-year average of 3162.55, near the low end of its estimated 5-year range (1.18–152235.19).

As of 2026-10-06T18:03:06.966Z. 336.59% above its estimated 12-month average of 3.41.

KROS PS Ratio Metrics

P/S vs. estimated history

At 14.88, P/S is below its estimated 6-year median — higher than 25% of readings in its estimated 6-year history.

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

Sales Valuation

PS Ratio Formula & Definition

PS Ratio = Market Cap / Revenue (TTM)

The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

PS Ratio FAQ

What is the P/S ratio for Keros Therapeutics, Inc. (KROS)?

The P/S ratio for KROS stock is 14.88.

Is Keros Therapeutics, Inc.'s P/S ratio high or low?

The P/S ratio of 14.88 is 100% below its estimated 5-year average of 3162.55, near the low end of its estimated 5-year range (1.18–152235.19).

What is the estimated TTM average P/S ratio for Keros Therapeutics, Inc. (KROS)?

The estimated TTM average P/S ratio for KROS stock is 3.41.

What is the estimated 3Y average P/S ratio for Keros Therapeutics, Inc. (KROS)?

The estimated 3Y average P/S ratio for KROS stock is 2927.06.

What is the estimated 5Y average P/S ratio for Keros Therapeutics, Inc. (KROS)?

The estimated 5Y average P/S ratio for KROS stock is 3162.55.

Showing the most recent 260 of 1,368 data points. The chart above shows the full history.

Related Metrics